ULK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, it has been showed that imatinib, a small molecule kinase inhibitor, facilitates K63-linked ULK1 ubiquitination subsequent in autophagy stimulation is critical for CML and perspectives for the treatment of CML CSCs treatment (Han et al., 2019).